Tolvaptan IR ( DrugBank: Tolvaptan )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
67	多発性嚢胞腎	2

67. 多発性嚢胞腎

---

臨床試験数 : 216 /  薬物数 : 219 - (DrugBank : 50) / 標的遺伝子数 : 39 - 標的パスウェイ数 : 151

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01451827 (ClinicalTrials.gov)	October 2011	11/10/2011	8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)	A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind, Placebo-masked, Parallel-group Pilot Trial to Compare the Efficacy, Tolerability, and Safety of Tolvaptan Modified-release and Immediate-release Formulations in Subjects With Autosomal Dominant Polycystic Kidney Disease	Autosomal Dominant Polycystic Kidney Disease	Drug: Tolvaptan MR;Drug: Tolvaptan IR;Drug: Placebo	Otsuka Pharmaceutical Development & Commercialization, Inc.	NULL	Completed	18 Years	50 Years	All	178	Phase 2	United States
2	NCT01210560 (ClinicalTrials.gov)	October 2010	21/9/2010	Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD	A Multi-center, Parallel-group, Randomized, Double-blind, Placebo-masked, Multiple Dose Trial of Modified-release (MR) and Immediate-release (IR) Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Autosomal Dominant Polycystic Kidney Disease	Drug: Tolvaptan MR;Drug: Tolvaptan IR	Otsuka Pharmaceutical Development & Commercialization, Inc.	NULL	Completed	18 Years	50 Years	All	25	Phase 2	United States